Your browser doesn't support javascript.
loading
T-Type Calcium Channels: A Potential Novel Target in Melanoma.
Barceló, Carla; Sisó, Pol; Maiques, Oscar; de la Rosa, Inés; Martí, Rosa M; Macià, Anna.
  • Barceló C; Oncologic Pathology Group, University of Lleida, IRBLleida, 25198 Lleida, Spain.
  • Sisó P; Oncologic Pathology Group, University of Lleida, IRBLleida, 25198 Lleida, Spain.
  • Maiques O; Centre for Cancer and Inflammation, Barts Cancer Institute, Queen Mary University of London, London EC1M 6BQ, UK.
  • de la Rosa I; Oncologic Pathology Group, University of Lleida, IRBLleida, 25198 Lleida, Spain.
  • Martí RM; Department of Dermatology, Hospital Universitari Arnau de Vilanova, University of Lleida, IRBLleida, 25198 Lleida, Spain.
  • Macià A; Centre of Biomedical Research on Cancer (CIBERONC), Instituto de Salud Carlos III (ISCIII), 28029 Madrid, Spain.
Cancers (Basel) ; 12(2)2020 Feb 08.
Article en En | MEDLINE | ID: mdl-32046241
ABSTRACT
T-type calcium channels (TTCCs) are overexpressed in several cancers. In this review, we summarize the recent advances and new insights into TTCC biology, tumor progression, and prognosis biomarker and therapeutic potential in the melanoma field. We describe a novel correlation between the Cav3.1 isoform and the increased basal autophagy in BRAFV600E-mutant melanomas and after acquired resistance to BRAF inhibitors. Indeed, TTCC blockers reduce melanoma cell viability and migration/invasion in vitro and tumor growth in mice xenografts in both BRAF-inhibitor-sensitive and -resistant scenarios. These studies open a new, promising therapeutic approach for disseminated melanoma and improved treatment in BRAFi relapsed melanomas, but further validation and clinical trials are needed for it to become a real therapeutic option.
Palabras clave